Tuesday, 30 June 2009

Cevimeline Hydrochloride (Evoxac) 30 mg Capsules: Innovator Daiichi sued Apotex

Innovator Daiichi has sued generic player Apotex for filing ANDA with Paragraph IV certification to market Cevimeline Hydrochloride (Evoxac) 30 mg Capsules. Innovator has sued Apotex in US district court for the district of Delaware. Following patents are listed in the Orange Book for this product:

US4855290 (Expiry: Aug 30, 2009): which covers various quinuclidine derivatives as product


US5340821 (Expiry: Jul 7, 2013): The patent covers a method for treating the symptoms of Sjoegren syndrome

As per complaint, innovator has alleged infringement of ‘821 patent by Apotex.

Innovator got approval to market Cevimeline (2-methyspiro (1,3- oxathiolane- 5,3) quinuclidine) Hydrochloride hydrate (Evoxac) 30 mg Capsules on Jan 11, 2000.

Cevimeline is a parasympathomimetic and muscarinic agonist and clinically used for the treatment of dry mouth associated with sjoegren syndrome

Posted by ADKS at 5:18 pm

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker